This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an eLetter
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Coghill, D.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Coghill, D.
Advances in Psychiatric Treatment (2003) 9: 86-94
© 2003 The Royal College of Psychiatrists

Current issues in child and adolescent psychopharmacology. Part 1: Attention-deficit hyperactivity and affective disorders

Dave Coghill

Dave Coghill is senior lecturer in child and adolescent psychiatry in the Department of Psychiatry, University of Dundee (Ninewells Hospital and Medical School, Dundee DD1 9SR, UK. Tel. 01382 204004; e-mail: david.coghill{at}tpct.scot.nhs.uk). He is also an honorary consultant child and adolescent psychiatrist in the Tayside Department of Child and Family Psychiatry. His main interests and research are in the neuropsychopharmacology of attention-deficit hyperactivity disorder and the psychopharmacology of child and adolescent psychiatric disorders. He is currently chair of the Royal College of Psychiatrists’ Faculty of Child and Adolescent Psychiatry Standing Group on Psychoactive Medication. He has received consultancy fees and travel costs by Janssen-Cilag and Eli Lilly.

Drug treatments play an important role in the treatment of child and adolescent psychiatric disorders. However, there is often a long delay before research findings are translated into clinical practice; furthermore, changes in clinical practice outstrip the available evidence. This paper focuses on current issues and research findings on the pharmacological treatment of attention-deficit hyperactivity disorder (ADHD) and affective disorders. Clinical findings from a US study of the treatment of ADHD with extended-release stimulants and non-stimulants, and the development and use of clinical guidelines are discussed. Clinical trials of selective serotonin reuptake inhibitors for early-onset depression, approaches to managing treatment-resistant depression and guidance on the drug treatment of early-onset mania are considered.




This article has been cited by other articles:


Home page
 Adv. Psychiatr. Treat.Home page
D. Coghill
Current issues in child and adolescent psychopharmacology. Part 2: Anxiety and obsessive-compulsive disorders, autism, Tourette's and schizophrenia
Adv. Psychiatr. Treat., July 1, 2003; 9(4): 289 - 299.
[Abstract] [Full Text] [PDF]

Home page
 Adv. Psychiatr. Treat.Home page
D. Cottrell
The APT online discussion forum
Adv. Psychiatr. Treat., March 1, 2003; 9(2): 84 - 85.
[Full Text] [PDF]